Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in <i>BRCA1</i> or <i>BRCA2</i> are biologically similar and sensitive to PARP inhibition
Brian Dougherty(AstraZeneca (United States)), J. Carl Barrett(Imperial College Healthcare NHS Trust), Mark J. O’Connor(AstraZeneca (United Kingdom)), Matthew Hawryluk(Foundation Medicine (United States)), Jonathan A. Ledermann(London Cancer), Roman Yelensky(National Vaccine and Serum Institute), Darren Hodgson(AstraZeneca (United Kingdom)), James Sun(Foundation Medicine (United States)), Timothy Brennan(GlobalFoundries (United States)), Wenting Wu(AstraZeneca (United States)), Jane Robertson(Cancer Research UK), Zhongwu Lai(AstraZeneca (United States)), Maria Orr(AstraZeneca (United Kingdom)), Tony W. Ho(Johns Hopkins University)
Cited by 4
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k